The Brigham and Women's Hospital, Inc.

Akamara Therapeutics, Inc.

Invictus Oncology Pvt. Ltd.

Vyome Therapeutics Limited

Massachusetts Institute of Technology

Ankara Therapeutics, Inc.

Vyome Biosciennces Pvt. Ltd.

Vyome Biosciences Pvt. Ltd.

Alyssum Therapeutic S, Inc.

Shiladitya Sengupta

Monideepa Roy

Ashish Kulkarni

Sumana Ghosh

Seikh Samad Hossain

Abhimanyu Paraskar

Aniruddha Sengupta

Anamika Bhattacharyya

Suresh Sadhasivam

Shamik Ghosh

Arindam Sarkar

Pradip Dutta

Nilu Jain

Nimish Gupta

Bhaskar Roy

Poornima Rao

Sudipta Basu

Shivani Soni

Poulomi Sengupta

Suresh Rameshlal Chawrai

Aasif Ansari

Sk Samad Hossain

Anubhab Mukherjee

Richard Buchta

Aaron Goldman

David Arthur Berry

Ram Sasisekharan

Sudhanand Prasad

Kristine Holley

Aarthi Chandrasekaran

Rajesh Sudhir Gokhale

Suresh Chawrai

Goutam Biswas

Nupar Tandon

Prithvi Raj Pandey

Sudip Roy

Ganlin Zhao

Dipankar Pramanik

Sazid Hussain

Kirti Bajaj

Mallika Mishra

D Sreedhar Reddy

Nidhi Arora

Sayali S Shah

Gauthami Mahesh

Abhijit S Bapat

Swadhin K Mandal

Hemant Suryavanshi

Sanghamitra Mylavarapu

Samad Hossain

Mau Sinha

Siva Ganesh Mavuduru

Deepak Kumar

Pradip Kumar Dutta

The present disclosure provides methods for treating cancer in a patient, comprising administering to the patient (i) a therapeutically effective amount of a compound of formula (VIII), or a pharmaceutically acceptable salt thereof, wherein Q, linker, and lipid are defined herein, and (ii) a therapeutically effective amount of an immune checkpoint inhibitor. Q-linker-lipid (VIII) In some embodiments, the compound is the following structure (10-125), or a pharmaceutically acceptable salt thereof: Pharmaceutical compositions comprising a compound of formula (VIII), such as 10-125, or a pharmaceutically acceptable salt thereof, an immune checkpoint inhibitor, and a pharmaceutically acceptable excipient are also described.

B-cell immunotherapy in cancer treatment

The current invention describes a conjugate of a targeting moiety linked to a drug via a molecule having high affinity for the targeting moiety at physiological pH such that the drug releases at low pH from the targeting moiety.

Targeted drug delivery through affinity based linkers

The disclosure provides a process of designing and optimizing supramolecular therapeutics. The disclosure also provides a method for designing and optimizing antibody drug conjugates.

Evaluation and optimization of supramolecular therapeutics

The present disclosure relates generally to novel molecules, compositions, and formulations for treatment of bacterial infections in general and more specifically to bacterial infections with antibiotic resistant pathogens.

Treatments for resistant acne

Described herein is a reporter material platform that can be used to directly monitor the drug response in real-time. The reporter material can include an activator element which undergoes a chemical change in response to an immunonological response to a drug, and the chemical change can be detected using a reporter element. The reporter material can include a drug and a reporter element that are physically constrained in a close proximity. The reporter element produces a signal only when the drug induces a direct or indirect physiological change in the tumor or surrounding tissue. The reporter material platform can self-assemble via supramolecular interactions. This reporter material platform can be used to directly monitor the drug response in real-time.

Reporter platform for real time monitoring of drug efficacy

The compositions and methods described herein relate to the treatment of cancer, e.g. by reducing the regression of cancer cells from regressing into cancer stem cell-like phenotypes and/or reducing the development of drug-resistant cancer cells. In some embodiments, the compositions and methods relate to inhibitors of PI3K pathway kinases and Src family kinases.

Methods and compositions relating to the treatment of cancer

The present disclosure relates generally to Cellular Signalling inhibitors of compound of Formula I, compositions and formulations comprising the same, methods, processes, and uses thereof. In particular, the present disclosure provides CSF-1R inhibitors demonstrating sustained inhibition of CSF/CSF1R signalling pathway with decreased toxicity. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a CSF-1R inhibitor is combined with one or more of a chemotherapeutic agent, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid. The present disclosure also provides a method for treating cancer, allergy, Systemic lupus erythematosus, nephritis, Chronic Obstructive Pulmonary Disease, and abnormal macrophage functions or any combinations thereof. 

Cellular signalling inhibitors, their formulations and methods thereof

The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to platinum based compounds comprising platinum moiety, linker moiety and lipid moiety and corresponding nanoparticles thereof. The disclosure further relates to synthesis of said platinum based compounds, nanoparticles and compositions comprising said platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by employing aforesaid carbene compounds, platinum based compounds, nanoparticles and compositions thereof.

Lipid-based platinum compounds and nanoparticles

Antibacterial therapeutics and prophylactics

The current invention discloses targeted drug delivery conjugates comprising a targeting moiety linked to a drug via a molecule having an affinity for the targeting moiety. Typically, the conjugate comprises a targeting ligand and a molecule of interest, e.g., a therapeutic agent. The targeting ligand and the molecule of interest are linked to each other via an affinity ligand. The affinity ligand is further covalently or non-covalently linked to a drug or therapeutic agent. The drug can be modified to make it more soluble and so that it cleaves from the linking molecule at the target site.

The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

Nanoscale platinum compounds and methods of use thereof

The present disclosure relates generally to supramolecular combinatorial therapeutics, compositions comprising same, and uses thereof. In particular, the present disclosure provides hydrophobic taxane-lipid covalent conjugates which create supramolecular assembly, for example, within lipid bilayer, providing an extra stabilization resulting in increased intratumoral concentration and hence increased efficacy. The present disclosure also provides supramolecular combinatorial therapeutics, wherein a taxane-lipid conjugate is combined with one or more of a platinum compound, a kinase inhibitor, and an immunoregulator, each of which is optionally conjugated with a lipid.

Supramolecular combinatorial therapeutics

Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.

Compositions for treating cancer and methods for making the same

Described are combination therapies and metabolically-activated drug conjugates and their use in treating cancer in subjects.

Metabolically-activated drug conjugates to overcome resistance in cancer therapy

Growing community of inventors

Waltham, MA, United States of America

Shiladitya Sengupta